Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cronos Group Inc T.CRON

Alternate Symbol(s):  CRON

Cronos Group Inc. is a Canada-based global cannabinoid company engaged in building intellectual property by advancing cannabis research, technology and product development. The Company operates through one segment, which is comprised of operations in Canada and Israel and is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s international brand portfolio includes Spinach, PEACE NATURALS, and Lord Jones. The Spinach brand offers pre-rolls infused with cold-filtered cannabis extract and coated in kief, and all-in-one disposable vapes. The Lord Jones is a hemp-derived cannabidiol (CBD) brand. Its Lord Jones Hash Fusions are a line-up of premium ice water hash infused pre-rolls. This brand also offers vapes and edibles. Its PEACE NATURALS offer Peppermint CBD, a blend of CBD extract, quality medium-chain triglycerides (MCT) oil, and a hint of natural peppermint flavor.


TSX:CRON - Post by User

Post by JayDesturaon Jun 03, 2022 3:49am
160 Views
Post# 34728654

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance


FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


 
<< Previous
Bullboard Posts
Next >>